A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer

Purpose: Lung cancer remains as the leading cause of cancer-related death worldwide, mainly due to late diagnosis. Cytology is the gold-standard method for lung cancer diagnosis in minimally invasive respiratory samples, despite its low sensitivity. We aimed to identify epigenetic biomarkers with clinical utility for cancer diagnosis in minimally/noninvasive specimens to improve accuracy of current technologies. Experimental Design: The identification of novel epigenetic biomarkers in stage I lung tumors was accomplished using an integrative genome-wide restrictive analysis of two different large public databases. DNA methylation levels for the selected biomarkers were validated by pyrosequencing in paraffin-embedded tissues and minimally invasive and noninvasive respiratory samples in independent cohorts. Results: We identified nine cancer-specific hypermethylated genes in early-stage lung primary tumors. Four of these genes presented consistent CpG island hypermethylation compared with nonmalignant lung and were associated with transcriptional silencing. A diagnostic signature was built using multivariate logistic regression model based on the combination of four genes: BCAT1, CDO1, TRIM58, and ZNF177. Clinical diagnostic value was also validated in multiple independent cohorts and yielded a remarkable diagnostic accuracy in all cohorts tested. Calibrated and cross-validated epigenetic model predicts with high accuracy the probability to detect cancer in minimally and noninvasive samples. We demonstrated that this epigenetic signature achieved higher diagnostic efficacy in bronchial fluids as compared with conventional cytology for lung cancer diagnosis. Conclusions: Minimally invasive epigenetic biomarkers have emerged as promising tools for cancer diagnosis. The herein obtained epigenetic model in combination with current diagnostic protocols may improve early diagnosis and outcome of lung cancer patients. Clin Cancer Res; 22(13); 3361–71. ©2016 AACR.

[1]  M. Esteller.  Epigenetic gene silencing in cancer: the DNA hypermethylome. , 2007, Human molecular genetics.

[2]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[3]  D. Dietrich,et al.  Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. , 2011, International journal of oncology.

[4]  Mithat Gonen,et al.  Nomograms in oncology: more than meets the eye. , 2015, The Lancet. Oncology.

[5]  J. Herman,et al.  Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung , 2008, Clinical Cancer Research.

[6]  G. Silvestri,et al.  A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. , 2015, The New England journal of medicine.

[7]  S. Belinsky,et al.  Gene-promoter hypermethylation as a biomarker in lung cancer , 2004, Nature Reviews Cancer.

[8]  Juna Lee,et al.  Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers , 2012, PloS one.

[9]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[10]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Hoque,et al.  Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Pallardó,et al.  Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities , 2013, Expert review of molecular diagnostics.

[13]  T. Liloglou,et al.  DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. , 2012, Cancer research.

[14]  R. Kaarteenaho.  The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis , 2013, Respiratory Research.

[15]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[16]  Christoph Bock,et al.  DNA methylation biomarkers in cancer: progress towards clinical implementation , 2012, Expert review of molecular diagnostics.

[17]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[18]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[19]  D. Aberle,et al.  Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.

[20]  P. Massion.  Biomarkers to the rescue in a lung nodule epidemic. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Dietrich,et al.  SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates , 2010, BMC Cancer.

[22]  O. Miettinen,et al.  Survival of Patients with Stage I Lung Cancer Detected on CT Screening , 2008 .

[23]  C. Dobler,et al.  Bronchoscopic diagnosis of endoscopically visible lung malignancies: should cytological examinations be carried out routinely? , 2009, Internal medicine journal.

[24]  M. Esteller,et al.  Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Tatematsu,et al.  Chemical genomic screening for methylation‐silenced genes in gastric cancer cell lines using 5‐aza‐2′‐deoxycytidine treatment and oligonucleotide microarray , 2006, Cancer science.

[26]  C. Moon,et al.  Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.

[27]  Peter Ulz,et al.  Circulating tumor DNA as a liquid biopsy for cancer. , 2015, Clinical chemistry.

[28]  T. Liloglou,et al.  Epigenetic biomarkers in lung cancer. , 2014, Cancer letters.

[29]  W. Lowrance,et al.  Predictive models for newly diagnosed prostate cancer patients. , 2009, Reviews in urology.

[30]  M. Esteller,et al.  Cancer epigenomics: beyond genomics. , 2012, Current opinion in genetics & development.

[31]  E. Tolley,et al.  Diagnosis of Lung Cancer: A Bronchoscopist’s Perspective , 2012, Journal of bronchology & interventional pulmonology.

[32]  B. Doyle,et al.  Pyrosequencing of DNA extracted from formalin-fixed paraffin-embedded tissue. , 2011, Methods in molecular biology.

[33]  Ronald C. Walker,et al.  Indeterminate Pulmonary Nodules: Risk for Having or for Developing Lung Cancer? , 2014, Cancer Prevention Research.

[34]  Lanjuan Li,et al.  Methylation Profile of Single Hepatocytes Derived from Hepatitis B Virus-Related Hepatocellular Carcinoma , 2011, PloS one.

[35]  F. Gilliland,et al.  Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.

[36]  Lawrence C. LaPointe,et al.  A panel of genes methylated with high frequency in colorectal cancer , 2014, BMC Cancer.

[37]  Young-Joon Kim,et al.  Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  K. Kelsey,et al.  A comparison of DNA methylation specific droplet digital PCR (ddPCR) and real time qPCR with flow cytometry in characterizing human T cells in peripheral blood , 2014, Epigenetics.

[39]  Frank Gannon,et al.  Epigenetic regulation in cancer progression , 2014, Cell & Bioscience.

[40]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[41]  J. Herman,et al.  Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer , 2014, Clinical Cancer Research.

[42]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[43]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[44]  S. Belinsky.  Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. , 2005, Carcinogenesis.

[45]  Rainer König,et al.  BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1 , 2013, Nature Medicine.

[46]  J. Herman,et al.  Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment , 2012, Clinical Cancer Research.

[47]  M. Esteller,et al.  Digital PCR quanti fi cation of MGMT methylation re fi nes prediction of clinical bene fi t from alkylating agents in glioblastoma and metastatic colorectal cancer , 2015 .

[48]  J. Eggert,et al.  Screening and Early Detection of Lung Cancer. , 2017, Seminars in oncology nursing.

[49]  Jinfeng Sun,et al.  Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. , 2012, Oncology letters.